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9 U. MASS. L. REV. 334
ABSTRACT
This Note addresses the issues related to fertility preservation treatments for cancer
patients in the context of insurance coverage. As cancer survival rates improve, the
ability to bear children after therapy is increasingly difficult and a concern for most
patients. Currently, no states have laws requiring insurance coverage for fertility
preservation treatments for cancer patients. Because it is not currently covered by
either private or public insurance, only those who can pay for it on their own can use
fertility preservation treatments. This Note proposes that Massachusetts, as having
one of the most inclusive infertility health insurance mandates, should expand
insurance coverage to those who may become infertile because of cancer treatments.
Such an expansion would ensure that cancer patients can receive fertility
preservation treatment prior to commencing chemotherapy or radiation. This Note
argues that insurance coverage should be extended because it improves a cancer
patient’s quality of life, and will promote consistency, fairness, and equality. Further,
this Note explores the constitutional implications of oncofertility.
AUTHOR
Candidate for Juris Doctor, University of Massachusetts School of Law, 2015; B.A.
English Literature, B.A. Writing, Rhetoric and Communications, University of
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I. INTRODUCTION
“The prospect of making it through cancer and then not
having children to share that with seemed a bit like a
death—a cut-off from the future.” Maria, 28, Ovarian
Cancer1

A

t twenty-eight years old, Maria Arruda found out that cancer took
her ability to have children too. After battling three years of
aggressive ovarian cancer, Maria felt a sense of defeat; something
treasured had been irretrievably lost, and there was nothing to be done
about it. Prior to chemotherapy, her doctor informed her that she could
undergo fertility preservation and freeze her eggs. Maria’s health
insurance coverage was small and Massachusetts did not even consider
covering medical costs for someone like her. On March 16, 2003, she
found out she could not have children. Her husband could not look at
her. She felt inside her somewhere, adjacent to or below the ailing
heart, a hungry, thirsty, empty, sore, haunted sensation of being
unfinished, random, and unattached, as if, even if the body were
working perfectly, there was nothing there for it to run.
She found herself looking forward to the night time. Sleep came
down so fast it was only in dreaming that she felt the peculiar new
thing: motherly. She imagined a daughter, having her lips, nose, and
chin, caressing each part of her as if she were a rose that a gardener
paused to admire. Her skin was soft and bright. Her hair was blonde
and curly, just like her mother’s. That little girl was part of her flesh—
flesh that wept, laughed, and danced on bare feet in the grass. Her
child, in reality, had no face, no form, no voice, and no odor. She was
a simple presence in her mind, an all-embracing tenderness with
strength and a promise of rest.
Cancer patients like Maria are more commonplace today than ever
before. Clinical infertility—the failure to conceive after a year of
trying—is particularly common among adults who receive pelvis
radiation and a class of chemotherapy drugs called alkylating agents.2
Over the years, advances in radiation and chemotherapy have
improved survival rates, but have significantly impacted the

1
2

Telephone interview with Maria Arruda (October 6, 2013) (on file with author).
Anahad O’Connor, After Cancer, Fertility is Often Within Reach, THE CENTER
FOR ADVANCED REPRODUCTIVE SERVICES (Mar. 27, 2014, 3:22PM),
http://fertilitycenter-uconn.org/after-cancer-fertility-is-often-within-reach/.
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reproductive capability of cancer survivors.3 Certain cancer treatments
induce infertility rates of eighty percent or more, and some treatments
estimate that up to ninety percent of cancer patients in their
reproductive years will be rendered infertile from treatment. 4
However, no states currently have laws providing for insurance
coverage for fertility preservation treatments for patients that had
cancer. 5 As a result, many patients are unable to have biologically
natural children after surviving the aggressive disease.
This Note argues that Massachusetts, as the leading state with the
most inclusive infertility coverage,6 should provide insurance coverage
for fertility preservation treatments for cancer patients about to receive
chemotherapy and radiation. Part II of this Note discusses cancer’s
unfortunate consequences on a patient’s reproductive system and their
options for treatment. Part III surveys the different issues regarding
insurance coverage for cancer patient fertility preservation treatment.
Lastly, Part IV discusses the current infertility law in Massachusetts
and suggests that Massachusetts should amend its current mandate by
adding a clause to cover people facing infertility due to cancer
treatment.
II. THE FIGHT TO SAVE TWO LIVES
“I was shocked. Then devastated. Never warned or
prepared about this possibility until after it happened. I
think the infertility was worse than the cancer.”
Marcia, 27, Ovarian Cancer7
A. The Emerging World of Oncofertility
Survival rates among young cancer patients have steadily increased
each year over the past four decades because of the development of

3

4

5
6
7

Seema Mohapatra, Oncofertility and Reproductive Justice, HARV. J. ON RACIAL
& ETHNIC JUST. (forthcoming 2014) (manuscript at 4) (on file with author).
Daniel Basco et al., Insuring Against Infertility: Expanding State Infertility
Mandates to Include Fertility Preservation Technology for Cancer Patients, 38
J.L. MED. & ETHICS 832, 836 (2010).
Mohapatra, supra note 3 (manuscript at 1).
Basco, supra note 4, at 832.
Marcia, Survivor Stories, FERTILE HOPE (Mar. 26, 2010), http://www.
fertilehope.org/find-support/cancer-survivor-stories-details.cfm?SID=641.
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effective cancer treatments.8 Increased survival is due to factors such
as earlier detection of disease, intensive radiation therapy, and new
chemotherapies. 9 Data collected by the National Cancer Institute
(“NCI”) reveals that there are 630,000 young survivors of cancer, and
that number is increasing each year.10 Twenty five percent of breast
cancer patients are younger than fourty years old, and over 12,400
adolescents under nineteen are diagnosed with cancer each year with a
cure rate of seventy-five percent. 11 Further, survival rates for
childhood cancer have increased from twenty percent to eighty-one
percent over the last forty years.12 Ultimately, as the NCI reports, one
out of every 250 adults will be a survivor of childhood cancer by
2015.13 This increased rate of survival among cancer patients is largely
attributable to the tremendous rise in cancer curing drugs. However,
one of the main complications of these cancer-curing drugs—
particularly for young men, women, and children—is the impact on
future fertility.14
“Oncofertility” is a new discipline that bridges the gap between
oncogology and new medicine in order to discover and apply new
fertility preservation options for young patients with cancer.15 Under
the emerging field of oncofertility, medical researchers are

8

9

10
11
12

13
14
15

The Oncofertility Consortium, About the Oncofertility Consortium,
NORTHWESTERN UNIVERSITY, http://oncofertility.northwestern.edu/about-us
(last visited December 15, 2013 ).
Teresa K. Woodruff, The Emergence of a New Interdiscipline: Oncofertility, in
ONCOFERTILITY: FERTILITY PRESERVATION FOR CANCER SURVIVORS 3, 3
(Teresa K. Woodruff & Karrie Ann Snyder eds., Springer 2007).
Id. at 4.
Id.
NAT’L CANCER INST., SEER CANCER STATISTICS REVIEW 1975–2005, at 31
tbl.I-3 (2008), available at http://seer.cancer.gov/archive/csr/1975_2005/results
_merged/sect_01_overview.pdf.
Woodruff, supra note 9, at 4.
See id. at 3.
The Oncofertility Consortium, About the Oncofertility Consortium,
NORTHWESTERN UNIVERSITY, http://oncofertility.northwestern.edu/about-us
(last visited Mar. 27, 2014). Dr. Woodruff, the Professor of Obstetrics and
Gynecology at Northwestern University, coined the term “oncofertility” in 2006
to incorporate life-after-cancer care with treating the disease. The goal of
oncofertility is to meet an emerging urgent unmet need for young cancer
patients: balancing life-preserving treatments with fertility-preserving options.
Id.
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investigating new approaches to preserve a cancer patient’s
reproductive options.16
In addition, oncofertility strives to close not only the gap between
oncology and new medicine, but also the wide information gap that
exists in today’s society.17 This information gap consists of the lack of
understanding that cancer patients have regarding the possibility of
infertility resulting from their cancer treatment. 18 Ultimately, many
doctors and oncologists focus on saving the patient’s life rather than
discussing the future possibility of infertility.19 However, oncofertility
stresses the importance of oncology providers to facilitate discussions
about fertility preservation and post-cancer quality of life. 20 It is
critical for clinicians to educate patients on their options for fertility
preservation early in the process for cancer risk management.
B. Infertility: Casualty of Cancer Treatment
Decreased fertility after cancer treatment is mainly caused by the
exposure to radiation and the alkylating agent chemotherapy. 21
Infertility is an unfortunate and likely result for many cancer patients,
with certain cancer treatments inducing infertility rates of eighty
percent or more.22 Some treatments estimate that up to ninety percent
of cancer patients in their reproductive years will be rendered infertile
from treatment.23 Rates of infertility vary according to cancer site, type
of treatment, and the age of a patient.24
There are many different fertility preservation options available to
newly diagnosed cancer patients. First, there are traditional options,
which include adoption and third-party reproduction. 25 Second,
16

17

18
19
20
21
22
23
24

25

See Gregory Dolin, Medical Hope, Legal Pitfalls: Potential Legal Issues in the
Emerging Field of Oncofertility, 49 SANTA CLARA L. REV. 673, 674 (2009).
See Brigid K. Martz, Learning to Bridge the Information Gap, THE
ONCOFERTILITY CONSORTIUM (Dec. 5, 2013), http://blog.oncofertility
.northwestern.edu/.
Id.
Id.
Id.
Dolin, supra note 16, at 673.
Basco, supra note 4, at 836.
Id.
G.P. Quinn et al., Frozen Hope: Fertility Preservation for Women with Cancer,
55 J. MIDWIFERY & WOMEN’S HEALTH 175, 175 (2010).
Third-party reproduction consists of gamete donation and/or uterine surrogacy
for cancer patients whose therapies diminished these functions. Dolin, supra
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assisted reproductive technology provides new and advanced ways to
preserve fertility.26 Technology is significantly advancing in the area
of fertility preservation after cancer treatment.27
In men, cancer itself may be correlated with low sperm counts.28
However, the primary threat for male cancer patients is a compromised
sperm production, quality, motility, and DNA damage caused by
exposure to chemotherapy and/or radiation. 29 The most proven and
successful method of fertility preservation for men is semen
cryopreservation, where patients provide semen samples which are
frozen for later use. 30 Intrauterine insemination or intracytoplasmic
sperm injection is extremely effective, as one single sperm may be
sufficient to result in a pregnancy. 31 The primary concern for male
cancer patients is to reach a sperm bank in a timely manner, as sperm
represent a ready and available source in large numbers and can be
cryopreserved easily.32
In women, cancer treatments pose a variety of reproductive risks
including immediate infertility, premature menopause, and
compromised ability to carry a pregnancy due to uterine or cervical
damage. 33 Women who undergo chemotherapy or radiation during
their reproductive years have a forty to eighty percent chance of losing
fertility.34 Chemotherapy and radiation can damage or destroy oocytes

26
27

28

29
30

31
32
33

34

note 16, at 683. These options are valuable means of forming a family, but do
not fulfill a woman’s or man’s desire to have biological children. See id. at 684.
See Dolin, supra note 16, at 684.
See Ina N. Cholst, Oncofertility: Preservation of Reproductive Potential, 61
DEPAUL L. REV. 763, 763 (2012).
FERTILE HOPE,CANCER AND FERTILITY: FAST FACTS FOR REPRODUCTIVE
PROFESSIONALS 5 (2008), available at http://www.fertilehope.org/uploads/pdf
/FH_RP_FastFacts_08.pdf.
Id.
See Dolin supra note 16, at 684. If the male cancer patient cannot obtain a
semen sample by ejaculatory methods because of the nature of his condition, a
surgical biopsy can be performed and mature sperm may be extracted. Id.
See id.
Id.
FERTILE HOPE, CANCER AND FERTILITY: FAST FACTS FOR ONCOLOGY
PROFESSIONALS 6 (2008) http://www.fertilehope.org/uploads/pdf/08_FH_Onc_
FastFacts.pdf [hereinafter CANCER AND FERTILITY: FAST FACTS].
Quinn, supra note 24, at 175. Infertility rates vary depending on many factors;
including cancer site, type of treatment, and the patient’s age. Infertility in
cancer patients can be caused by the cancer or the type of cancer treatment that
is involved. Exact infertility rates are not known because no valid measures exist
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and follicles, which can cause either immediate or premature
menopause years after treatment. 35 In addition, surgery to remove
reproductive organs such as the ovaries, fallopian tubes, uterus, and
cervix will reduce a woman’s ability to become pregnant or carry a
child.36 In addition, radiation can damage the uterus and increase the
risk of miscarriage or low-birth weight.37
A number of treatments are available for infertility for women but
are more limited than those available to men. 38 The most common
fertility preservation procedure is in vitro fertilization (“IVF”).39 There
are also experimental options available such as in vitro maturation or
ovarian tissue freezing. 40 The most well-established treatment,
however, is to undergo ovarian stimulation for maturation and retrieval
of the eggs.41 The oocytes are fertilized on the day of egg retrieval and

35
36
37
38

39

40

41

for women to establish that fertility was present prior to treatment. However,
women who undergo chemotherapy or radiation during their reproductive years
have a forty to eighty percent chance of losing fertility. Treatments using the
alkylating agents of cyclophosphamide, methotrexate, and fluorouracil produce
the greatest risk for infertility. Further, total body radiation and external beam
radiation also produces great risks for infertility. Id.
CANCER AND FERTILITY: FAST FACTS, supra note 33, at 6.
Id.
Id.
Dolin, supra note 16, at 684. Many techniques that are used, including embryo
and oocyte cryopreservation, require hormonal stimulation, which is problematic
and thus poses many limitations. Cancer treatment must be delayed when
undergoing stimulation procedures, but it is imperative that a patient begin
treatment immediately after cancer diagnosis. In addition, ovarian stimulation
may elicit reactions from hormonally responsive cancers, such as breast and
ovarian cancers. See id. at 685.
CANCER AND FERTILITY: FAST FACTS, supra note 33, at 12. With IVF, doctors
retrieve eggs from a woman’s ovary after hormonal stimulation of the ovaries,
fertilize the eggs with sperm in a petri dish, and transfer some of the embryos to
the woman’s uterus. The remaining embryos are frozen for future use. See David
Orenlicher, Discrimination Out of Dismissiveness: The Example of Intfertility,
85 IND. L.J. 143. 154.
In vitro maturation involves removing immature oocytes and then maturing
them in vitro. CANCER AND FERTILITY: FAST FACTS, supra note 33, at 12. Once
matured, the oocytes can either be frozen or fertilized to create embryos and
then frozen. Ovarian tissue freezing involves the removal, sectioning and
freezing of an ovary. The ovarian strips can be transplanted later to restore
hormonal function and for use with IVF. Id.
Sanjay K. Agarwal & R. Jeffrey Chang, Fertility Management for Women with
Cancer, in ONCOFERTILITY: FERTILITY PRESERVATION FOR CANCER SURVIVORS,
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the resultant embryos are cryopreserved.42 The embryos can be thawed
and transferred into either the patient’s own uterus, providing that her
uterus is viable for pregnancy, or that of another woman as a
gestational surrogate. 43 The success rates for these procedures are
dependent upon the woman’s age at the time the eggs were retrieved
and fertilized.44
Traditional infertility patients are often able to receive infertility
treatment until they are able to conceive, which differs dramatically
from cancer patients. 45 Cancer patients have only one substantial
chance at preserving fertility because they are only able to receive
fertility treatment before they begin cancer treatment.46 Consequently,
cancer patients typically undergo treatment immediately or shortly
after their diagnosis, giving them a short period of time to utilize
fertility preservation treatment.
C. Insurance Coverage for Fertility Preservation Treatments
Insurance companies do not typically cover fertility preservation
treatments because they are commonly viewed as elective procedures
rather than medically necessary.47 Infertility resulting from radiation or
chemotherapy is typically known as an iatrogenic condition. 48
Insurance companies generally cover treatment for iatrogenic
conditions that result from cancer treatment, even though they do not

42
43
44
45
46
47

48

at 6 (2007), http://oncofertility.northwestern.edu/sites/default/files/uploadedfile
content/onco_chapter_2.pdf.
Id. at 6.
Id.
Id. at 7.
Basco, supra note 4, at 834.
Id.
Lisa Campo-Englestein, Insurance Coverage for Cancer Treatment Induced
Conditions: Comparing Fertility Preservation to Breast Reconstructive Surgery,
61 DEPAUL L. REV. 849, 854 (2012).
Id. at 854.An iatrogenic condition is a negative side effect or adverse condition
that is caused by the diagnosis, manner, activity, or treatment of a healthcare
provider. Id. Specifically, in relation to cancer, we refer to infertility as a
nonnegligent iatrogenic condition, which occurs when medically necessary
treatments have unavoidable or unpredictable negative side effects. For
example, this may occur when cancer treatment causes infertility, hair loss, or
nausea in a patient. Id. at 850.
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cover these same conditions when they are naturally occurring. 49
However, infertility treatment is typically not covered.50
Most health-care plans will not reimburse patients or physicians
for the cost of IVF or other technologies to assist reproduction, and
even when insurance provides coverage, it typically is inadequate.51
Twelve states mandate insurance coverage for infertility treatments,
and two states require that coverage be offered.52 However, it appears
that no state currently provides insurance coverage specifically for
fertility preservation treatment for cancer patients. When an insurance
company denies fertility preservation coverage, there is a minimal
amount of time to appeal.53 Consequently, cost and lack of insurance
coverage are major reasons why many female patients do not undergo
fertility preservation treatment.54
The costs of fertilization preservation treatments and procedures
vary.55 The price to receive information and advice about procedures
49
50
51

52
53

54

55

Id. at 851.
Id.
Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers,
Indelible Harms, 23 BERKELEY J. GENDER, L.& JUST. 18, 22 (2009).
Id.
Mohapatra, supra note 3 (manuscript at 3); Nat’l Conference of State
Legislatures, State Laws Related to Insurance Coverage for Infertility Treatment
(May 2009), http://www.ncsl.org/programs/health/50infert.htm.
A study conducted from January 2011 to October 2012 surveyed reproductive
aged women with cancer who were being counseled by a reproductive health
clinic for fertility preservation. Patients completed surveys at four different
points in time, including before and after a new patient consultation, at the time
they made a decision about fertility preservation, and six to eight months after
consultation. The possible reasons for not undergoing fertility preservation
included: risks to fertility from cancer treatment, cost, lack of insurance
coverage, age, delay of cancer treatment, and future pregnancy’s effect on long
term prognosis. Ninety-four women were surveyed, and fifty-two percent of
women did not undergo FP, ninety percent of which identified cost and lack of
insurance coverage as the reason for not undergoing treatment. See E.E.
Niemasik, et. al., It Comes Down to Money: Why Women Decide Not to
Undergo Fertility Preservation, 98 FERTILITY AND STERILITY S122 (2012); see
also DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND
POLITICS DRIVE THE COMMERCE OF CONCEPTION 30 (2006) (“In this market,
therefore, price acts harshly as a constraint on demand. The desire is there, as we
know. So, increasingly, is the supply. Yet the price of this supply is still too high
for many potential buyers, leaving supply and demand to meet at a point well
below their full potential.”).
Elizabeth A. Pendo, The Politics of Infertility: Recognizing Coverage Exclusions
as Discrimination, 11 CONN. INS. L.J. 293, 300 (2005).
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typically only cost the amount of a general office visit.56 Further, the
price of treatment intrauterine insemination is typically only a few
hundred dollars.57 However, estimates for IVF range from $8,000 to
$10,000 per procedure, and patients usually must undergo more than
one procedure during this process.58 Below, in Table 1, is a summary
of the average prices of the most common fertility preservation
treatments.59
Table 1: Summary Statistics of Fertility Preservation Prices

Avg.
Price

Oocyte
Cryopreservation
$6608

Embryo
Cryopreservation
$8285

Sperm
Cryopreservation
$244

Sperm
Storage
$381
annually

Many different views exist as to why insurance coverage is not
extended to cancer patients. First, many of the most effective assisted
reproductive technologies are deemed experimental and many insurers
do not cover experimental procedures.60 Further, insurance companies
typically cover conditions that currently exist or conditions that are
certain to occur, and infertility is not definite.61 Even after a patient
undergoes fertility preservation procedures, the embryos, eggs, or
ovarian tissue may not be used until some later time in the far future.62
Finally, insurance companies find that fertility preservation is vastly
complex when compared to other side effects of cancer because it
affects the patient’s family and future offspring.63 These views will be
addressed and challenged thoroughly in Part IV.64

56
57
58
59

60
61
62
63
64

Id.
Id.
Id.
Fertility Preservation for Cancer Patients: Demographic Disparities in
Counseling and Financial Concerns are Barriers to Utilization, AMERICAN
SOCIETY FOR REPRODUCTIVE MEDICINE (Oct. 23, 2013), http://www.socrei.org
/Fertility_Preservation_for_Cancer_Patients_Demographic_Disparities_in_Coun
seling_and_Financial_Concerns_Are_Barriers_to_Utilization/.
Mohapatra, supra note 3 (manuscript at 14).
Id.
Id.
Id.
See infra Part IV.
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Despite the criticism, oncofertility is making its way to the
insurance sphere. Currently, Connecticut, 65 Hawaii, 66 New Jersey, 67
and California68 have bills pending that deal with fertility preservation
insurance coverage specifically for cancer patients. The California
Bill, in particular, would require a health care service plan and a health
insurer to provide, on a group and individual basis, coverage for
medically necessary expenses for standard fertility preservation
services when a necessary medical treatment may directly or indirectly
cause iatrogenic infertility.69 Further, the United States Congress also
has a bill pending for a similar goal.70 The Family Act of 2013 has
been introduced into both the U.S. Senate and U.S. House of
Representatives—S 881/HR 1851, respectively—and will provide
critical financial support for young people with cancer, autoimmune
disorders, and other conditions whose treatment may save their lives
yet damage their ability to have children in the future.71 The Family
Act will create a tax credit for eligible taxpayers to cover fifty percent
of the cost of IVF and fertility preservation up to the maximum
amount set by the ATC—$12,970 this calendar year.72
Further, in June 2013, the American Medical Association (AMA)
adopted a policy that supports coverage by all insurance providers of
fertility preservation treatment for cancer patients undergoing
treatments “that may result in infertility”. 73 The AMA stated that
65
66
67
68
69

70

71
72
73

A.B. 5644, Gen. Assembly Reg. Sess. (Conn. 2013).
H.B. 2105, 26th Leg., Reg. Session (Haw. 2012).
A.B. 2479, 215th Leg., 1st Session (N.J.2012).
A.B. 912, Reg. Session (Cal. 2013-2014).
Id. The fiscal effect of Bill AB 912 was found to result in approximately
$69,000 of additional costs to the California Public Employees’ Retirement
System for additional premiums and unknown costs, potentially greater than
$100,000, to the extent the fertility treatment preservation services exceed the
Essential Health Benefits (EHB) of the Affordable Care Act (ACA). QuirkSilva, Bill Analysis for A.B. 912, Reg. Session (Cal. 2013-2014) 1, available at
http://leginfo.ca.gov/pub/13-14/bill/asm/ab_0901-0950/ab_912_cfa_20130624_
135304_sen_comm.html.
See H.R. 1851, 113th Cong., 1st Session (2013). S.B. 881, 113th Cong., 1st
Session (2013).
Id.
Id.
AMA Adopts New Policies on First Day of Voting at Annual Meeting,
AMERICAN MEDICAL ASSOCIATION (June 17, 2013), http://www.amaassn.org/ama/pub/news/news/2013/2013-06-17-new-ama-policies-annualmeeting.page#.
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coverage for infertility treatments “should be an essential part of the
management of [patients] cancer.”74 This policy treats infertility as a
side-effect of treatment or a negative condition created by cancer.75
Consequently, it is slowly being recognized that the need for fertility
preservation treatment is a result of a medical condition and not just a
desired elective procedure.76
III. CURRENT LAW: MASSACHUSETTS AND FERTILITY COVERAGE
“I am saddened that so many people not only have to
go through cancer and the treatments required just to
overcome this disease and be able to live, but also have
to worry about whether or not they will ever become
parents.” Thomas, 34, Testicular Cancer77
In 1987, Massachusetts passed the Act Providing a Medical
Definition of Infertility (“Infertility Act”). 78 RESOLVE, a national
infertility advocacy group based in Massachusetts, began pushing for
an insurance mandate.79 This advocacy group wanted infertility to be
labeled as a medical condition necessitating treatment, removing it
from the sphere of a cosmetic problem to a medical problem.80 Thus,
the confluence of interests created a mandate to include insurance
coverage requirements for infertility services at the same level as
pregnancy-related services.81
In Massachusetts, infertility refers to the condition of an individual
who is unable to conceive or produce conception during a period of
one year if the female is age 35 or younger or during a period of six
months if the female is over the age of 35.82 Under the mandate, all
74
75

76
77

78

79
80
81
82

Id.
Angela Krausfeldt, Support for Fertility Preservation Now an AMA Policy!, THE
ONCOFERTILITY CONSORTIUM (June 28, 2013), http://blog.oncofertility
.northwestern.edu/2013/06/support-for-fertility-preservation-is-now-an-amapolicy/.
Id.
Thomas, Survivor Stories, FERTILE HOPE (March 26, 2010), http://www
.fertilehope.org/find-support/cancer-survivor-stories-details.cfm?SID=626.
See K. Cullen, Law Orders Coverage for Infertility, BOSTON GLOBE, October 9,
1987.
Basco, supra note 4, at 833.
Id.
Id.
211 C.M.R. § 37.03 (2012).
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insurers providing pregnancy-related benefits shall provide for the
diagnosis and treatment of infertility, including the following: artificial
insemination; IVF; GIFT; sperm, egg, and/or inseminated egg
procurement and processing; and banking of sperm of inseminated
eggs, to the extent such costs are not covered by the donor’s insurer.83
Under the mandate, however, insurers are not required to cover, but
are not prohibited from recovering, experimental infertility procedures,
surrogacy, reversal or voluntary sterilization.84 Further, Massachusetts
insurance companies and HMPs must cover “the medically necessary
expenses of diagnosis and treatment of infertility.” 85 The statute
further places limits to the same extent as they are provided for other
pregnancy-related procedures and—subject to the other terms and
conditions of the subscription certificate—coverage for medically
necessary expenses of diagnosis and treatment of infertility.86
Massachusetts’ infertility mandate is one of the most inclusive
health insurance mandates regulating coverage for infertility services
in the United States.87 The Massachusetts mandate creates a review
system that allows for additional infertility services to be covered as
medical technology advances and procedures move from experimental
to routine.88 Unlike other states, Massachusetts’ mandate places few
limitations on covered procedures.89 However, the mandate still fails
to include patients who face infertility due to cancer treatment.
The Affordable Care Act (“ACA”) is unlikely to have a dramatic
impact on infertility care and does not directly address infertility
coverage.90 However, the law does give states the power to determine
the scope of insurance coverage for a variety of medical conditions

83
84
85
86
87
88
89
90

See 211 MASS. CODE. REGS. § 37.05 (2013).
211 MASS. CODE. REGS. § 37.07 (2013).
MASS. GEN. LAWS ANN. ch. 175, § 47H (West 2010).
MASS. GEN. LAWS ANN. ch. 176B § 4J (West 2010).
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and procedures, including infertility.91 Consequently, ACA does little
to standardize the state-mandated insurance policies dealing with the
diagnosis and treatment of infertility. 92 The ACA does require that
health plans offered in the small group and individual markets cover
Essential Health Benefits (“EHBs”) effective January 1, 2014, but this
does not necessarily include infertility treatment.93 As Massachusetts
currently mandates coverage for infertility treatment, it also included
the infertility mandate in its Benchmark plan. 94 Thus, in
Massachusetts, infertility treatment is an essential benefit.95 It might
therefore be said that, because the ACA does not mandate infertility
treatment, it does not pose an incredible disadvantage or even make a
big difference in infertility treatment via insurance coverage.96
Unfortunately, while extremely inclusive, the mandate primarily
affects those who have health insurance and who meet the
Massachusetts definition of infertility. The Massachusetts mandate
essentially is designed for a “presumably healthy individual.” 97
Unfortunately, cancer patients are not included under the definition of
infertility in Massachusetts because cancer patients are not considered
physiologically or medically infertile at the time when fertility
preservation treatment would take place.98 Therefore, it is under the
assumption that medicine is reactive, treating conditions that already
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Brezina, supra note 90, at 195. The ACA could facilitate access to fertility
treatments in mandated states. First, the ACA will make health insurance
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exist, rather than being proactive in preventing conditions from
existing in the future.99
Under existing state law, a cancer patient is considered part of the
general population with regard to the class of persons protected by
laws relating to infertility.This is problematic because cancer survivors
have characteristics that set them apart from the general population
intended to be addressed by fertility insurance law.100 The language of
the law itself attests to the non-applicability of its provisions to cancer
patients, particularly young, unmarried men and women.101 Therefore,
cancer survivors would have to wait until they met the clinical
definition of infertility before attempting to use insurance benefits.102
This is unlikely because chemotherapy and radiation are prone to
render a patient without viable sperm or eggs, and the most likely
chance of success will come from the sperm or eggs harvested before
the initiation of cancer treatment.103
IV. SOLUTION: EXTENDING FERTILITY PRESERVATION COVERAGE
TO CANCER PATIENTS
“Having breast cancer made me want children even
more. When you are faced with your own mortality
each day, you want to make sure you leave some sort of
legacy behind.” Tonya, 21, Breast Cancer104
A. Proposed Legislation and Implementation
Massachusetts should provide insurance coverage for fertility
preservation procedures for cancer patients about to receive
chemotherapy and radiation, both of which often cause infertility.
Treatment to preserve fertility in men and women can be done before
chemotherapy or radiation and can be used after the patient is free of
cancer.105 Particularly, Massachusetts should add a clause to its current
99
100
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mandate extending fertility preservation insurance coverage to cancer
patients. With this legislation, Massachusetts would create a separate
and different definition of infertility for cancer patients and survivors.
Thus, although cancer patients would not be able to meet the standard
definition of infertility, they would be able to meet the separate
definition of infertility set out in the amended mandate. The added
clause may look as follows, as modeled by the California Bill A.B.
912106:
(1) Every group or individual health care service plan that is
issued, amended, or renewed on and after January 1, 2016, that
provides hospital, medical, or surgical coverage shall include
coverage for medically necessary expenses for standard fertility
preservation services when a necessary medical treatment may
directly or indirectly cause iatrogenic infertility to an enrollee.
(2) For purposes of this section, the following terms have the
following meanings:
(a) “Standard fertility preservation services” means
procedures consistent with established medical practices
and professional guidelines published by the American
Society of Reproductive Medicine, the American Society
of Clinical Oncology, or other reputable professional
organizations.
(b) “May directly or indirectly cause” means treatment
with a likely side effect of infertility as established by the
American Society for Reproductive Medicine, the
American Society of Clinical Oncology, or other
reputable professional organizations.

The current Massachusetts mandate gives the Massachusetts
Commissioner of Insurance the authority to establish a list of required
and optional infertility benefits, along with the authority to oversee the
process of adding new procedures to what would be covered. 107 In
order for a new procedure to be added, an individual must petition the
commissioner to recognize the procedure as fundamental or nonexperimental.108 This process has allowed for the mandate to evolve as
medical technology advances without the need for further legislative
steps.109
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With the increase in survival rates and decrease in fertility due to
new and advanced cancer-curing drugs, the commissioner may amend
the existing mandate, as modeled above, to include cancer patients.
The mandate would ultimately provide separate standards for cancer
patients to meet the definition of infertility. This is an extremely
beneficial and workable option, as it recognizes that cancer patients
have limited time to preserve their fertility before beginning treatment
that is likely going to render them infertile. Massachusetts should
implement this flexible policy with the insurance mandate so that the
mandate will evolve as technology advances. Thus, with medical
technology and advances in cancer survival, it is plausible for
Massachusetts to take this route and extend coverage for cancer
patients in this way.
Further, health insurance mandates have become extremely
popular in the United States, especially those specifically centered on
cancer. 110 From 2000 to 2003, an average of seventy six health
insurance mandates were passed per year, which rose from fifty nine
mandates per year during the 1990s.111 Every state now has at least
one health insurance mandate applying to cancer.112 For example, all
states now have legislation regulating coverage for breast
reconstructive surgery after surviving breast cancer and many states
also address coverage for diagnosing prostate cancer.113 As mandates
are becoming more common place, it may be reasonable to predict that
an addition to a mandate will be passed for cancer patients to receive
infertility treatment insurance coverage.
B. Why Should Coverage Be Extended?
In one study of cancer survivors, seventy-six percent of those who
were childless expressed a desire to have biological children in the
future. 114 Most fertility preservation treatments and procedures for
cancer patients are not covered by insurance, even in Massachusetts
which has mandated IVF coverage. Those who are unable to have
children because of certain cancer treatments thus must pay out of
110
111
112
113
114
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pocket for further treatment for infertility. As discussed more below,
this section suggests that coverage for infertility preservation should
be expanded to cancer survivors due to the issues of quality of life,
fairness, consistency, equality, and certain constitutional
considerations.
1. Quality of Life
The inability to reproduce, although not life-threatening or
harmful, adversely affects a person’s quality of life tremendously. Men
and women typically do not expect to be infertile, and news of
infertility comes as a severe shock. 115 Consequently, infertility is
extremely emotionally distressing. Psychological responses to
infertility range from surprise, denial, anxiety, anger, guilt, low selfesteem, isolation, hopelessness, feelings of unfulfillment, social
withdrawal, and depression.116 Those who experience infertility also
experience changes to their perceptions of their lives. This can include
feelings of an inability to plan the future, the inability to find meaning
in life, and the overgeneralization of loss of control over reproduction
to other aspects of life.117
Many studies have found that infertility patients also find infertility
to be one of the most upsetting experiences of their lives.118 In addition
to a cancer diagnosis, many people deal with infertility as they would a
loss of a loved one.119 Infertility brings not only the loss of the ability
to have children, but the loss of pregnancy, childbirth, and
breastfeeding, and experiences of genetic continuity, parenthood, and
relationships. 120 Ultimately, cancer patients may also deal with
subsequent repercussions of infertility that require more extensive
medical appointments, testing, medication, surgeries, physical pain,
numerous unfortunate side effects, fear, grief, and psychological
identity adjustment.121
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Mandating insurance coverage for fertility preservation thus has
the power to transform the quality of life for cancer survivors. 122
Without insurance coverage, patients may opt out of fertility
preservation, which may result in high costs for the survivor years later
when he or she is trying to build a family and create a life after cancer,
and further enforce the feelings of anguish and grief that patients’
experience. 123 If men and women have the option to preserve their
fertility before undergoing treatment—and have the opportunity to
afford it—they will not have to deal with these other devastating
effects of cancer and their quality of life will improve greatly.
In terms of financial impact, expanding this coverage is only for a
relatively small number of people during their reproductive years and
will only minimally impact insurance premiums when spread out
amongst all insured persons. 124 Without such coverage, patients are
unable to afford this unexpected out-of-pocket expense, especially
when facing other significant costs surrounding the cancer treatment
itself.125 A study conducted in 1998 revealed that mandated infertility
coverage was associated with increased use of assisted reproductive
technology, but there were no excessive increases in consumer cost for
infertility insurance coverage.126 While expanding coverage to include
infertility treatment for cancer patients may increase demand because
of the lower costs to patients, these increases would be small
considering the limited number of people who are diagnosed with
cancer at the heart of their reproductive age.127 For example, one study
demonstrated that if utilization of IVF rose to a high of three hundred
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70 FERTILITY AND STERILITY 22, 22 (1998). Cost data was obtained from the
Massachusetts Department of Insurance Rate-Setting Commission and nine
large group insurance plans for the period of 1986–1993 and examined the
utilization and success rates of ART. Id. Infertility services amounted for 0.41%
of total expenditures within the indemnity plan in 1993. Id.
Id.

354

UMass Law Review

v. 9 | 334

percent as a result of expansion, premiums would only increase about
nine dollars per employee per year.128
Further, although nontraditional parenting is becoming more
prominent in today’s society, the options of adoption and the use of
donor gametes and surrogacy should not substitute extending
insurance coverage all together. Cancer survivors face significant
obstacles when dealing with non-biological parenting options. 129
Options such as these are costly, and adoption is typically restricted to
young and healthy married couples. 130 In order to adopt a child,
agencies frequently require documentation and proof that cancer
survivors have been disease-free for at least five years. 131 These
options may provide an individual with the means of forming a family,
but fail to fulfill the desire of many individuals to making a family.
Thus, these options do not vastly improve a patient’s quality of life.
2. Consistency and Fairness
Health care providers often provide for certain measures to prevent
iatrogenic conditions from occurring. 132 Almost every side effect of
cancer and its treatment is covered by health insurance except for
infertility.133 First, insurance covers antiemetics for nausea and dental
evaluations for osteoradionecrosis.134 Other conditions resulting from
cancer, such as hair loss, are also covered under insurance.135 Scholars
have compared infertility treatments to breast reconstruction
procedures, which are also covered by insurance. 136 Covering
infertility treatment for cancer patients with iatrogenic infertility
ultimately creates consistency and fairness in policy coverage, rather
128

129

130
131
132
133

134
135
136

Jessica L. Hawkins, Separating Fact from Fiction: Mandated Insurance
Coverage of Infertility Treatments, 23 WASH. U. J.L. & POL’Y 203, 221 (2007).
Clarisa R. Garcia & Jacqueline S. Jeruss, Lives in the Balance: Women With
Cancer and the Right to Fertility Care, 31 J. CLINICAL ONCOLOGY 1, 2 (2013),
available at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.47.5798.
Id.
Id.
Basco, supra note 4, at 834.
See Triaging Fertility Preservation & the AMA, TRIAGE CANCER (July 1, 2013),
http://triagecancer.org/blog/triaging-fertility-preservation-the-ama/.
Basco, supra note 4, at 834.
Campo-Engelstein, supra note 47, at 856.
Id. at 854. The Women’s Health and Cancer Rights Act of 1998 mandated that if
insurers covered mastectomy (breast removal), then they must also cover breast
reconstruction. Id.

2014

Maria's Law

355

than treating infertility differently than other iatrogenic conditions that
are covered.
Although insurance companies rarely cover experimental
procedures, many fertility preservation treatments are no longer
considered experimental by scientists.137 The freezing of a woman’s
eggs has become increasingly ordinary, with seventy to ninety percent
of eggs surviving the process. 138 Further, the technology of egg
preservation and freezing is improving rapidly.139 Most importantly,
egg and ovarian tissue cryopreservation are the only options available
for young or single women to be able to have a child in the future with
someone without a sperm donor. 140 Fertility preservation options
should be available for single women to have a biological child in the
future with the person of their choice.
Although infertility cannot be calculated to an exact certainty—
like hair loss or the loss of a breast—this should not preclude
insurance coverage of the condition. For instance, insurance
companies provide coverage for nausea, although it may not be
absolutely certain to occur.141 They also cover storing one’s blood as a
prophylactic precaution in case there needs to be an emergency
transfusion, which also cannot be predicted. 142 Similarly, patients
undergoing cancer treatment also may find themselves rendered
infertile, and thus fertility preservation treatment, like blood storage,
should be saved in that “just-in-case” scenario. This speaks to
consistency and fairness, and Massachusetts should set the way for
insurance to cover iatrogenic infertility.
Cancer patients are simply not responsible for their infertility, and
not providing them insurance coverage for a medical implication out
of their control promotes unfairness. However, for example, it is
possible, albeit crass, to suggest that a woman who seeks fertility
preservation treatment to address age-related infertility is responsible
for her own condition because she intentionally delayed her childbearing; yet this is covered by insurance.143 It would be equally absurd
to suggest that a patient with cancer—who is typically not “causally
137
138
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responsible” for his or her condition 144 —who decides to have
treatment that could result in infertility should not get insurance
coverage for his or her condition. Rather, our present system forces a
cancer patient to ultimately choose between two losses: the loss of life
or the loss of fertility.145 Because there is no causal responsibility, as it
is out of a cancer patient’s control, and because insurance companies
already cover other “possible” side effects, insurance companies
should extend their own policies and extend coverage.
3. Equality
An insurance mandate that is extended to cancer patients can create
a sense of equality in certain ways. First, anecdotal evidence from
Massachusetts suggests that because the state recognizes same-sex
marriages and gives equal insurance benefits regardless of marriage,
coverage may be expanded to include same-sex couples and could
expand to unmarried cancer patients.146 Second, equality among men
and women can be considered when dealing with extending the
infertility mandate to cancer patients. Fertility preservation treatment
is a lot cheaper for men than it is typically for women. 147 Thus,
extending insurance coverage for cancer patients will allow women
more affordable options for treatment that are closer in price to their
male counterparts.
Inequality is not created by extending coverage because those who
will never need infertility treatments have to pay for them. The
purpose of health insurance, ultimately, is to pool risks in order to
provide affordable health care for all members. 148 Those who are
insured pay into the insurance pool, hoping they will never have to
utilize it.149 On the contrary, infertile couples or individuals must pay
for others’ maternity and childbirth expenses that they are unable to
use, diminishing any trace of unfairness or inequality.150
144
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4. Constitutional Considerations
Finally, although the courts have not considered the issue of
fertility preservation treatment and cancer directly, the rights to
reproduce and bear children are rooted in American law and should be
taken into consideration. The Supreme Court has recognized the ability
to have children as a fundamental right.151 Further, the Supreme Court
has established that reproduction is a central role in the lives of many
individuals, and has also labeled reproduction as a major life
activity. 152 Cases involving the right to use contraceptives further
demonstrate that the right to make decisions regarding sexual activities
and reproduction is a substantive due process right, as the Supreme
Court has protected a married couple’s right to use contraceptives in
Griswold v. Connecticut. 153 Thus, the Court described reproductive
freedom as “intimate to the degree of being sacred.” 154 The Court
extended the protection beyond married couples to single individuals
in Eisenstadt v. Baird, holding that the right to privacy encompasses
the right of a single individual to make his or her own decisions as to
whether “to bear or beget a child.”155 Taking it even further, in Ohio v.
Akron Center for Reproductive Health, the Supreme Court extended
this right to minors.156
While no state explicitly protects a right to use assisted
reproductive technology (“ART”) or procedures such as IVF, both
state and federal governments implicitly acknowledge that such a right
exists.157 As Massachusetts mandates insurance coverage for IVF, it
necessarily recognizes the legality of ART to support citizens’ access
to these services. 158 Thus, some courts currently acknowledge that
procreative liberty encompasses, subject to state and judicial

151

152

153
154
155
156
157
158

See Skinner v. Oklahoma, 316 U.S. 535, 541 (1942) (“We are dealing here with
legislation which involves one of the basic civil rights of man. Marriage and
procreation are fundamental to the very existence and survival of the race.”).
See Bragdon v. Abbot, 524,U.S. 624, 638 (1998) (“Reproduction falls well
within the phrase ‘major life activity.’ Reproduction and the sexual dynamics
surrounding it are central to the life process itself.”).
See Griswold v. Connecticut, 381 U.S. 479, 485–86 (1965).
Id. at 486.
Eisenstadt v. Baird, 405 U.S. 438, 453 (1972).
Ohio v. Akron Ctr. For Reprod. Health, 497 U.S. 502, 506–07 (1990).
Dolin, supra note 16, at 679.
Id. at 678–79.

358

UMass Law Review

v. 9 | 334

regulation, the right to use ART.159 Not allowing cancer patients to
undergo fertility preservation treatment under the current mandate
therefore inhibits their right to reproduction, creating various
constitutional concerns. Not being able to afford these procedures, a
patient should therefore argue that this inhibits their substantive due
process right to make decisions about reproduction.
5. Further Concerns and Comments
The area of oncofertility raises a number of moral and ethical
questions. Among these concerns are the ethical implications of
removing and freezing embryos; the question of who can consent to a
procedure; property ownership of the reproductive material; and the
control of the reproductive tissue if the patient has died.160 Questions
of financing, religious objections, and access must be considered.161
The emerging field of oncofertility creates new hope and possibilities
for individuals whose fertility may be compromised by cancer
treatment and it is a field that is still growing. The Oncofertility
Consortium continues to expand their analysis on such legal and
ethical implications, striving for patients to have the ability to have
children and to exercise their freedom to make reproductive decisions
in the most ethical and legal manner.162
V. CONCLUSION
“I remember seeing a picture in my breast surgeon’s
office that has a list of things that cancer cannot do.
And I wanted that to include that it couldn’t take
pregnancy away from us. Even if we never use the eggs
or get pregnant on our own, it would be a blessing. I
refer to my frozen eggs as my pocket full of sunshine.”
Michele Foust, 26, Breast Cancer163
Advances in medicine and technology now allow young cancer
patients the option of preserving their fertility, and it is important that
these patients have the monetary tools necessary to do so. The
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technology exists that allows cancer patients to enter survivorship with
the option to have a biological child, but is out of reach due to
extensive costs.164 As the emerging field of oncofertility continues to
grow, insurance companies will be faced with how to handle infertility
for cancer patients. Amending the Massachusetts infertility mandate to
include cancer patients is an equitable and cost-effective solution to a
foreseeable harm from medically necessary treatment. This
amendment to the mandate not only symbolizes the importance of
fertility preservation treatment and the severity of infertility as a
disease, but also opens the door for more discussions between patients
and providers about fertility preservation treatment. Further, the
amendment would improve a patient’s quality of life, and create a
sense of fairness, consistency, and equality that is currently lost.
The success rates for infertility treatments continue to improve,
and a more expansive insurance coverage is likely to lead to more
effective treatments while lowering the risks of infertility associated
with cancer. For an individual or a couple who receives news of
possible infertility, it can be devastating. Indeed, there is a dark irony
in the fact that medical technology exists to enable them to have a
child, but health insurance does not provide coverage for them.
Although Massachusetts provides infertility coverage to the general
public, it is simply not enough, as it excludes cancer patients. The
amendment to the mandate would include a tragically excluded
population while keeping costs low. Most importantly, the amended
mandate would enable cancer patients to fulfill one of the most basic
and beloved human desires: creating a family.
After going through cancer and divorce battles, Maria now lives
alone and constantly contemplates what life would be like if she never
had cancer. She now lives in a society which indicated in every
possible way that she was a broken woman, with thin hair and cracked
eyebrows, with not a lash left on her eye. Her therapist suggested
writing her thoughts down, and she decided to try, for she had nothing
left to lose.
She sits on her porch, with great wounds, beginning to scratch in a
notebook. The moon was about in the same position it was always in,
and provided enough light on her notebook to write. With tired hands
and wet eyes, she picked up a pen and began to write: “At twenty-eight
years old, I found out that cancer took my ability to have children too.”
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